Mother And Child Medical Services

[Home][What's New][Products & Services][Contents][Feedback][Search]

The information contained at the Jachabacha Web site should not be used as a substitute for the medical care and advice of your physician. Information provided here pertains to Medicine in general. There may be variations in treatment recommended by your physician based on individual facts and circumstances. 

IN NO EVENT SHALL MOTHER AND CHILD MEDICAL SERVICES BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE INFORMATION OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THIS WEB SITE.

Mother To Child Transmission


Back To MCMS Health And Medicine Journal.....Doorin.gif (3582 bytes)

 

Focusing On Antiretroviral Therapy For Prevention Of Maternal To Fetal HIV Transmission

 

Regimens

 

q       Long Course Zidovudine Treatment

 

q       Short Course Zidovudine Treatment

 

q       Combination Therapy

 

Long Course Zidovudine Treatment

 

Period Of Time

Route

Dosage (ZDV)

 

 

 

During Pregnancy, initiate at 14 - 34 wks gestation

Oral

100mg 5 times a day

 

 

 

During Labour And Delivery

Intravenous

2mg /kg during the first hour (loading), then 1mg / kg / hour until delivery

 

 

 

For The Newborn, Beginning 8-12 Hours After Birth

Oral

2mg /kg 4 times a day

 

 

 

The Trial:

 

Pediatrics AIDS Clinical Trial Group (PACTG 076)

 

 

 

§       But Data Suggest From Thailand And Brazil Suggest A Good Efficacy Of This Regimen

 

ü   Women given ZDV (100mg 5times a day) Or Placebo starting at 14-34 weeks (median 26 weeks)

 

ü   Received ZDV during Labour and Delivery. Newborns received ZDV at 8-12 hours as mentioned above

 

ü   All mothers had CD4 counts > 200 were symptom free and had not received antiretrovirals before

 

Results Of The PACTG076 trials

 

HIV Transmission Rate

ZDV Treated Group

Placebo Group

8.3%

25.5%

Almost 67% reduction in transmission (356 mother child groups analysed)

 

References:

 

AIDS Clinical Trials Group Protocol (Center For Disease Control And Prevention), Recommendations for use of of zidovudine to reduce perinatal transmission of human immunodeficiency virus, MMWR, 1994; 43 (No. RR - 11) I-20

 

Data From Red Book, American Academy Of Pediatrics, 1997

 

Data From Who Paper HIV In Pregnancy : A Review

 

Newell M-L, Gray G, Bryson YJ. Prevention of mother to child HIV - I transmission. AIDS, 1997, 11 (Suppl A) : S165-S172

Certain Limitations When Applied To The Developing Countries:

 

q       The Study reviewed only non - breast feeding mothers

 

q       Cost: The Regimen costs about US$ 1000

 

q       Intervention needs to be introduced early when most women in resource poor countries attend antenatal care late in pregnancy

 

The use of shorter regimens or other antiretrovirals provides an alternative

Short Course Zidovudine Treatment

 

ü   More feasible in resource poor countries

 

The Bangkok Perinatal AZT Study, 1996:

 

ü   Randomized placebo controlled trial

 

ü   All women given infant feeding formula and advised not to breast feed

 

Period Of Time

Route

Dosage (ZDV)

 

 

 

From 36 weeks Pregnancy Till Onset Of Labour

Oral

300mg twice daily

 

 

 

Onset Of labour Till Delivery

IV

300mg every 3 hours

Results Of The Bangkok Perinatal AZT Study

 

HIV Transmission Rate

ZDV Treated Group

Placebo Group

9.4%

18.9

Almost 50% reduction in transmission (May 1996 - December 1997 : 393 mother child pairs analysed)

 

 

Reference:

 

Schaffer N et al. Short Course zidovudine for perinatal HIV - 1 transmission in Bangkok, Thailand: a randomized control trial. Lancet March 1999, 353 : 773 - 80

 

 

 

 

The Cote d'Ivoire Trial:

 

ü   Randomized placebo controlled trial

 

ü   Over 95% of the infants were breast fed

 

Period Of Time

Route

Dosage (ZDV)

 

 

 

From 36 weeks Pregnancy Till Onset Of Labour

Oral

300mg twice daily

 

 

 

Onset Of labour Till Delivery

Oral

300mg every 3 hours

 

Results Of The Cote d'Ivoire Trial

 

HIV Transmission Rate

ZDV Treated Group

Placebo Group

19 Of 115 Babies (16.5%)

30 Of 115 Babies (26%)

Almost 36% reduction in transmission (119 mother child groups analysed)

 

Reference:

 

Dasbis F et al for the DITRAME Study Group 6 month efficacy, tolerance and acceptability of a short course regimen of zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire : a double blind placebo control multicentric trial. Lancet, 1999, 353 : 786-92

 

Combination Therapy

 

The UNAIDS co-ordinated PETRA trial using Zidovudine + Lamivudine

 

ü   Study still in progress but interim results at 6 weeks of age infants available

 

ü   Compares 3 different regimes versus a placebo in Breastfeeding Population

 

Drugs: Zidovudine + Lamivudine

Drug Arm

Therapy

 

 

A

From 36 weeks Pregnancy, During Labour And For One Week Post Partum To Both Mother And Child

B

From Onset Of Labour And For One Week Post Partum To Both Mother And Child

C

During Labour Only

 

Results Of The UNAIDS co-ordinated PETRA trial

 

Drug Arm

HIV Transmission Rates

 

ZDV Treated Group

Placebo Group

 

 

 

A

8.6%

 

17.7%

B

10.8%

C

17.2%

(1790 mother child groups analysed)

 

Others - Nevirapine: Efficacy studies have commenced on Neirapine (NNRTI) as the drug achieves high circulating levels which are long lasting  raising the possibility of a one dose treatment in labour : Results Awaited

Thank You.

Send In Your Comments To jachabacha@yahoo.com

Back To MCMS Health And Medicine Journal.....Doorin.gif (3582 bytes)


[Home][What's New][Products & Services][Contents][Feedback][Search]

Send mail to CompanyWebmaster with questions or comments about this web site.
Copyright © 2000 CompanyLongName
Last modified: February 28, 2002